Overview

Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
0
Participant gender:
All
Summary
We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University
Peking Union Medical College Hospital
RenJi Hospital
Sir Run Run Shaw Hospital
The Central Hospital of Lishui City
The First Affiliated Hospital of Zhejiang Chinese Medical University
Treatments:
Rifaximin
Criteria
Inclusion Criteria:

- 18-75 years old;

- in line with the diagnostic criteria of diarrhea-type irritable bowel syndrome Roman
IV;

- blood routine, blood biochemistry, stool examination and colonoscopy within 2 years
are no problem;

- no intestinal warning symptoms

Exclusion Criteria:

- suffering from severe heart, lung, liver, kidney, nervous system diseases;

- suffering from mental disorders caused by schizophrenia, brain organic and physical
diseases;

- suffering from other diseases that may affect intestinal function (such as diabetes,
thyroid disease);

- History of previous abdominal surgery (excluding history of cholecystectomy or
appendectomy);

- pregnant or lactating women;

- have undergone colonoscopy in the past month or accept other bowel preparation
operations;

- In the past 1 month, have used antibiotics, antidiarrheal agents, intestinal flora
regulation, Chinese medicine and other drugs;

- have participated in other dietary treatments;

- understand communication barriers, unable to communicate